Interactions between endocannabinoid and serotonergic systems in mood disorders caused by nicotine withdrawal

Nicotine and Tobacco Research

Volumn 13, Issue 4, 2011, Pages 239-247

  Mannucci, Carmen ^a   Navarra, Michele ^b   Pieratti, Antonella ^a   Russo, Giuseppina A ^a   Caputi, Achille P ^a,b   Calapai, Gioacchino ^a  

^a School of Legal Medicine   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NICOTINE; SEROTONIN 1A RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; DRUG MECHANISM; FORCED SWIMMING TEST; LOCOMOTION; MALE; MOOD DISORDER; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; WESTERN BLOTTING; WITHDRAWAL SYNDROME;

EID: 79956111908     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntq242     Document Type: Article

References (51)

1. Balerio, G. N., Aso, E., Berrendero, F., Murtra, P., & Maldonado, R. (2004). Delta9-tetrahydrocannabinol decreases somatic and motivational manifestations of nicotine withdrawal in mice. European Journal of Neurosciences, 20, 2737-2748. doi:10.1111/j.1460-9568.2004.03714.x.
2. Balerio, G. N., Aso, E., & Maldonado, R. (2006). Role of cannabinoid system in the effects induced by nicotine on anxiety-like behavior in mice. Psychopharmacology, 184, 504-513. doi:10.1007/s00213-005-0251-9.
3. Balfour, D. J., & Ridley, D. L. (2000). The effects of nicotine on neural pathways implicated in depression: A factor in nicotine addiction? Pharmacology Biochemistry and Behavior, 66, 79-85. doi:10.1016/S0091-3057(00)00205-7.
4. Bambico, F. R., Duranti, A., Tontini, A., Tarzia, G., & Gobbi, G. (2009). Endocannabinoids in the treatment of mood disorders: Evidence from animal models. Current Pharmaceutical Design, 15, 1623-1646. doi:10.2174/138161209788168029.
5. Basavarajappa, B. S., & Hungund, B. L. (2002). Neuromodulatory role of the endocannabinoid signalling system in alcoholism: An overview. Prostaglandins Leukotrienes Essential Fatty Acids, 66, 287-299. doi:10.1054/plef.2001.0352.
6. Calapai, G., Crupi, A., Firenzuoli, F., Inferrera, G., Squadrito, F., Parisi, A., et al. (2001). Serotonin, norepinephrine and dopamine involvement in the antidepressant action of hipericum perforatum. Pharmacopsychiatry, 34, 45-49. doi:10.1055/s-2001-15180.
7. Calapai, G., Squadrito, F., Rizzo, A., Marciano, M. C., Campo, G. M., & Caputi, A. P. (1995). Multiple action of the coumarine derivate cloricromene and its protective effects on ischemic brain injury. Naunyn Schmiedeberg's Archives of Pharmacology, 351, 209-215. doi:10.1007/BF00169335.
8. Castañé, A., Valjent, E., Ledent, C., Parmentier, M., Maldonado, R., & Valverde, O. (2002). Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence. Neuropharmacology, 43, 857-867. doi:10.1016/S0028-3908(02)00118-1.
9. Catania, M. A., Firenzuoli, F., Crupi, A., Mannucci, C., Caputi, A. P., & Calapai, G. (2003). Hypericum perforatum attenuates nicotine withdrawal syndrome in mice. Psycopharmacology, 169, 186-189. doi:10.1007/s00213-003-1492-0.
10. Chemin, J., Monteil, A., Perez-Reyes, E., Nargeot, J., & Lory, P. (2001). Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. EMBO Journal, 20, 7033-7040. doi: http://dx.crossref.org/10.1093%2Femboj%2F20.24.7033.
11. Chen, R. Z., Frassetto, A., & Fong, T. M. (2006). Effects of the CB1 cannabinoid receptor inverse agonist AM251 on food intake and body weight in mice lacking mu-opioid receptors. Brain Research, 1108, 176-178. doi:10.1016/j.brainres.2006.06.006.
12. Covey, L. S., Glassman, A. H., & Stetner, F. (1998). Cigarette smoking and major depression. Journal of Addictive Diseases, 17, 35-46. doi:10.1300/J069v17n01_04.
13. Cryan, J. F., & Leonard, B. E. (2000). 5-HT1A and beyond: The role of serotonin and its receptors in depression and the antidepressant response. Human Psychopharmacology, 15, 113-135. doi:10.1002/(SICI)1099-1077(200003)15:2<113::AID-HUP150>3.0.CO;2-W.
14. Cryan, J. F., Valentino, R. J., & Lucki, I. (2005). Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neuroscience & Biobehavioral Reviews, 29, 547-569. doi:10.1016/j.neubiorev.2005.03.008.
15. De Vries, T. J., & Schoffelmeer, A. N. (2005). Cannabinoid CB1 receptors control conditioned drug seeking. Trends in Pharmacological Sciences, 26, 420-426. doi:10.1016/j.tips.2005.06.002.
16. Degroot, A., & Nomikos, G. G. (2007). In vivo neurochemical effects induced by changes in endocannabinoid neurotransmission. Current Opinion in Pharmacology, 7, 62-68. doi:10.1016/j.coph.2006.11.001.
17. Fletcher, P. J., Lê, A. D., & Higgins, G. A. (2008). Serotonin receptors as potential targets for modulation of nicotine use and dependence. Progress in Brain Research, 172, 361-383. doi:10.1016/S0079-6123(08)00918-7.
18. Gaetani, S., Cuomo, V., & Piomelli, D. (2003). Anandamide hydrolysis: A new target for anti-anxiety drugs? Trends in Molecular Medicine, 9, 474-478. doi:10.1016/j.molmed.2003.09.005.
19. Godlewski, G., Gothert, M., & Malinowska, B. (2003). Cannabinoid receptor-independent inhibition by cannabinoid agonists of the peripheral 5-HT3 receptor-mediated von Bezold-Jarisch reflex. British Journal of Pharmacology, 138, 767-774. doi:10.1038/sj.bjp.0705114.
20. Gonzalez, S., Cascio, M. G., Fernandez-Ruiz, J., Fezza, F., Di Marzo, V., & Ramos, J. A. (2002). Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Research, 954, 73-81. doi:10.1016/S0006-8993(02)03344-9.
21. Gonzalez, S., Valenti, M., de Miguel, R., Fezza, F., Fernandez-Ruiz, J., Di Marzo, V., et al. (2004). Changes in endocannabinoid contents in reward-related brain regions of alcohol-exposed rats and their possible relevance to alcohol relapse. British Journal of Pharmacology, 143, 455-464. doi:10.1038/sj.bjp.0705963.
22. Gorzalka, B. B., Hill, M. N., & Sun, J. C. (2005). Functional role of the endocannabinoid system and AMPA/kainate receptors in 5-HT2A receptor-mediated wet dog shakes. European Journal of Pharmacology, 516, 28-33. doi:10.1016/j.ejphar.2005.04.019.
23. Haj-Dahmane, S., & Shen, R. Y. (2009). Endocannabinoids suppress excitatory synaptic transmission to dorsal raphe serotonin neurons through the activation of presynaptic CB1 receptors. Journal of Pharmacology and Experimental Therapeutics, 331, 186-196. doi:10.1124/jpet.109.153858.
24. Howlett, A. C., Blume, L. C., & Dalton, G. D. (2010). CB(1) cannabinoid receptors and their associated proteins. Current Medicinal Chemistry, 17, 1382-1393. doi:10.2174/092986710790980023.
25. Isola, R., Vogelsberg, V., Wemlinger, T. A., Neff, N. H., & Hadjiconstantinou, M. (1999). Nicotine abstinence in the mouse. Brain Research, 850, 189-196. doi:10.1016/S0006-8993(99)02131-9.
26. Kenny, P. J., & Markou, A. (2001). Neurobiology of the nicotine withdrawal syndrome. Pharmacology Biochemistry and Behavior, 70, 531-549. doi:10.1016/S0091-3057(01)00651-7.
27. Le Foll, B., Forget, B., Aubin, H. J., & Goldberg, S. R. (2008). Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: Insights from pre-clinical and clinical studies. Addiction Biology, 13, 239-252. doi:10.1111/j.1369-1600.2008.00113.x.
28. Linthorst, A. C. E., Penalva, R. G., Flachskamm, C., Holsboer, F., & Reul, J. M. H. M. (2002). Forced swim stress activates rat hippocampal serotonergic neurotransmission involving a corticotropin-releasing hormone receptor dependent mechanism. European Journal of Neuroscience, 16, 2441-2452. doi:10.1046/j.1460-9568.2002.02400.x.
29. Maingret, F., Patel, A.J., Lazdunski, M., & Honoré, E. (2001). The endocannabinoid anandamide is a direct and selective blocker of the background K(+) channel TASK-1. EMBO Journal, 20, 7-54. doi: http://dx.crossref.org/10.1093%2Femboj%2F20.1.47.
30. Maldonado, R., & Berrendero, F. (2010). Endogenous cannabinoid and opioid systems and their role in nicotine addiction. Current Drug Targets, 11, 11440-11449. doi:10.2174/138945010790980358.
31. Mannucci, C., Tedesco, M., Bellomo, M., Caputi, A. P., & Calapai, G. (2006). Long-term effect of nicotine on the forced swimming test in mice: An experimental model for the study of depression caused by smoke. Neurochemistry International, 49, 481-486. doi:10.1016/j.neuint.2006.03.010.
32. Navarro, M., Hernandez, E., Munoz, R. M., del Arco, I., Villanua, M. A., Carrera, M. R., et al. (1997). Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport, 8, 491-496. Retrieved from http://journals.lww.com/neuroreport/pages/articleviewer.aspx?year=1997&issue=01200&article=00023&type=abstract.
33. Nicholson, R. A., Liao, C., Zheng, J., David, L. S., Coyne, L., Errington, A. C., et al. (2003). Sodium channel inhibition by anandamide and synthetic cannabimimetics in brain. Brain Research, 978, 194-204. doi:10.1016/S0006-8993(03)02808-7.
34. Oz, M., Jackson, S. N., Woods, A. S., Morales, M., & Zhang, L. (2005). Additive effects of endogenous cannabinoid anandamide and ethanol on alpha7-nicotinic acetylcholine receptor-mediated responses in Xenopus oocytes. Journal of Pharmacology and Experimental Therapeutics, 313, 1272-1280. doi:10.1124/jpet.104.081315.
35. + current by ethanol in follicle-enclosed oocytes. Naunyn-Schmiedeberg's Archives of Pharmacology, 367, 80-85. doi:10.1007/s00210-002-0643-x.
36. Oz, M., Tchugunova, Y., & Dinc, M. (2004a). Differential effects of endocannabinoid and synthetic cannabinoids on voltage-dependent calcium fluxes in rabbit T-tubule membranes: Comparison with fatty acids. European Journal of Pharmacology, 502, 47-58. doi:10.1016/j.ejphar.2004.08.052.
37. Oz, M., Zhang, L., & Morales, M. (2002). Endogenous cannabinoid, anandamide acts as a non-competitive inhibitor on 5-HT3 receptor-mediated response in Xenopus oocytes. Synapse, 46, 150-156. doi:10.1002/syn.10121.
38. 7-nicotinic receptor mediated currents in Xenopus oocytes. Journal of Pharmacology and Experimental Therapeutics, 310, 1152-1160. doi:10.1124/jpet.104.067751.
39. Paperwalla, K. N., Levin, T. T., Weiner, J., & Saravay, S. M. (2004). Smoking and depression. Medical Clinics of North America, 88, 1483-1494. doi:10.1016/j.mcna.2004.06.007.
40. Patel, S., & Hillard, C. J. (2006). Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety:Further evidence for an anxiolytic role for endogenous cannabinoid signaling. Journal of Pharmacology and Experimental Therapeutics, 318, 304-311. doi:10.1124/jpet.106.101287.
41. Patel, S., Roelke, C. T., Rademacher, D. J., Cullinan, W. E., & Hillard, C. J. (2004). Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology, 145, 5431-5438. doi:10.1210/en.2004-0638.
42. Paterson, N. E., & Markou, A. (2007). Animal models and treatments for addiction and depression co-morbidity. Neurotoxicity Research, 11, 1-32. doi:10.1007/BF03033479.
43. Piomelli, D. (2003). The molecular logic of endocannabinoid signalling. Nature Reviews Neuroscience, 4, 873-884. doi:10.1038/nrn1247.
44. + channels. Neuropharmacology, 35, 983-991. doi:10.1016/0028-3908(96)00130-X.
45. Porsolt, R. D., Anton, G., Blayet, N., & Jafre, M. (1978). Behavioral despair in rats: A new model sensitive to antidepressant. European Journal of Pharmacology, 47, 379-391. doi:10.1016/0014-2999(78)90118-8.
46. Porsolt, R. D., Le Pichon, M., & Jalfre, M. (1977). Depression: A new model sensitive to antidepressant treatments. Nature, 266, 730-732. doi:10.1038/266730a0.
47. Salin-Pascual, R. J., Rosas, M., Jimenez-Genchi, A., Rivera-Meza, B., & Delgado-Parra, V. (1996). Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major depression. Journal of Clinical Psychiatry, 57, 387-389. Retrieved from http://www.psychiatrist.com/default2.asp.
48. Sonne, S. C., Nunes, E. V., Jiang, H., Tyson, C., Rotrosen, J., & Reid, M. S. (2010). The relationship between depression and smoking cessation outcomes in treatment-seeking substance abusers. American Journal of Addiction, 19, 19111-19118. doi:0.1111/j.1521-0391.2009.00015.x.
49. Vázquez-Palacios, G., Bonilla-Jaime, H., & Velázquez-Moctezuma, J. (2005). Antidepressant effects of nicotine and fluoxetine in an animal model of depression induced by neonatal treatment with clomipramine. Progress in Neuropsychopharmacology and Biological Psychiatry, 29, 39-46.
50. Viveros, M. P., Marco, E. M., & File, S. E. (2005). Endocannabinoid system and stress and anxiety responses. Pharmacology Biochemistry and Behavior, 81, 331-342. doi:10.1016/j.pbb.2005.01.029.
51. Zaniewska, M., McCreary, A. C., Wydra, K., & Filip, M. (2010). Effects of serotonin (5-HT)2 receptor ligands on depression-like behavior during nicotine withdrawal. Neuropharmacology, 58, 1140-1146. doi:10.1016/j.neuropharm.2010.02.006.